Treatment of Advanced Retinoblastoma with Syngeneic Bone Marrow Transplantation

Authors

  • Surapon Wiangnon Department of Pediatrics, Faculty of Medicine, Khon Kaen University
  • Allen R. Chen Pediatric Oncology, Bone Marrow Transplant Program, The John Hopkins Hospital, Baltimore, MD, USA
  • Feffry Dome Pediatric Oncology, Bone Marrow Transplant Program, The John Hopkins Hospital, Baltimore, MD, USA
  • Issarang Nuchprayoon Department of Pediatric, Faculty of Medicine, Chulalongkorn University
  • Barbara Schmeckpeper Immunogenetics Laboratories, The Johns Hopkins Medical Institute, Baltimore, MD, USA
  • Wilma B. Bias Immunogenetics Laboratories, The Johns Hopkins Medical Institute, Baltimore, MD, USA
  • Curt I. Civin Pediatric Oncology, Bone Marrow Transplant Program, The John Hopkins Hospital, Baltimore, MD, USA

Keywords:

Retinoblastoma, Syngeneic bone marrow transplantation

Abstract

Abstract: High dose multiagent chemotherapy followed by syngeneic bone marrow rescue was used in the treatment of two patients with advanced bilateral retinoblastoma. The first patient presented with classical heritable retinoblastoma and his identical twin was also affected. He received multi-modality treatment inchuding radiotherapy, chemotherapy and enucleation. The disease recurred and locally invaded 42 months after diagnosis. The second patient underwent enucleation after diagnosis of a large mass of retinoblastoma with vitreous seeding and retinal detachment. No additional treatment was given. The disease recurred 11 months after diagnosis in the other eye and metastasized to liver and bone marrow. Although he received intensive chemotherapy, CNS metastases developed. Syngeneic BMT was used in the treatment of both patients. The preparative regimen consisted of carboplatin, etoposide, and cyclosphamide. A self-limited clical syndrome grade II-GVHD was observed in both patients. The transplant course was complicated by reversible renal insufficiency, and elevated liver transaminase in the second patient. The frst patient remains progression free to date. The second patient had recurent CNS disease and expired 3 months after bone marrow transplantation.

Downloads

Download data is not yet available.

References

Donaldson SS, Egbert PR, Newsham I, Cavenee WK. Retinoblastoma. In: Pizzo PA, Poplack DG, eds. Principles and Practice of Pediatric Oncology. Philadelphia: JB Lippincott-Raven; 1997.699-715.

Shields JA, Shields CL. Current Management of Retinoblastoma. Mayo Clin Procedure 1994;69:50-6.

Tamboli A, Podgor JM, Horm WJ, et al. The incidence of retinoblastoma in United States; 1974 through 1985. Arch Ophtalmol 1990;108:128.

Zelter M, Daniel A, Gonzales G, Schwartz L. A prospective study on the treatment of retinoblastoma in 72 patients. Cancer 1991;68:1685-90.

Doz F, Khelfaoui F, Mosseri V, et al. 'The role of chemotherapy in orbital involvement of retinoblastoma: The experience of a single institution with 33 patients. Cancer 1994, 74, 722-32.

White L. Chemotherapy in retinoblastoma: current status and future directions. Am Pediatr Hematol Oncol 1991;13:189-201.

White L. Chemotherapy for retinoblastoma: where do we go from here? Ophthalmic Paediatr Genet. 1991;12:115-30.

Saarinen UM, Sariola H, Hovi L. Recurrent disseminated retinoblastoma treated by high-dose chemotherapy, total body irradiation, and autologous bone marrow rescue. Am J Pediatr Hematol Oncol 1991;13:315-9.

Van Riet I, Schots R, Balduc N, et al. Immunomagnetic purging of bone marrow grafts for autologous transplantation in neuroblastoma. Acta Clinica Belgica 1990;45:97-106.

Yaniv I, Bouffet E, Irle C, et al. Autologous bone marrow transplantation in pediatric solid tumors. Hematol Onco Pediatr 1990;7:35-46.

Ekert H, Tiedemann K, Waters KD, Ellis WM. Experience with high-dose multiagent chemotherapy and autologous bone marrow rescue in the treatment of twenty-two children with advanced tumors. Aust Paediatr J 1984;20:195-201.

Ekert H, Ellis WM, Waters KD, Tauro GP. Autologous bone marrow rescue in the treatment of advanced tumors of childhood cancer. Cancer 1982;49:603-9.

Saleh RA, Gross S, Cassano W, Gee A. Metastatic retinoblastoma successfully treated with immunomagnetic purged autologous bone marrow transplantation. Cancer 1988;62:2301-3.

Parkes SE, Amaoku KWM, Muir KR, Willshaw HE, Mann JR. Thirty years retinoblastoma (1960-89): changing pattern of incidence. Paediatr Perinatal 1994;8:282-91.

Fontanesi J, Pratt C, Meyer D, Elverbig J, Parham D, Kaste S. Asynchronous bilateral retinoblastoma: the St. Jude Children's Research Hospital experience. Ophthalmic Genet 1995;16:109-12.

Peterson RA, Friend SH, Albert DM. Prolonged survival of a child with metastatic retinoblastoma. J Pediatr Ophthalmol Strabismus 1987;24:242-8.

Ishii E, Matsuzaki A, Ohnishi Y, Kai T, Ueda K. Successful treatment with ranimustine and carboplatin for recurrent intraocular retinoblastoma with vitreous seeding. Am J Clin Oncol 1996;19:562-5.

Doz F, Neuenschwander S, Plantaz D, et al. Etoposide and carboplatin in extraocular retinoblastoma: A study by the Societe Francaise d'Oncologie Pediatrique. J Clin Oncol 1995;13:902-9.

Wiley JM, Leventhal BG, Fresia A. High dose carboplatin (CBDCA), etoposide (VP-16) and cyclophosphamide (CY) with autologous bone marrow rescue (ABMR) in children and young adults with refractory solid or brain tumors. Proc ASCO 1993;10:1975-81.

Wiley JM, Frasia A, Strauss L. High dose carboplatin (CBDCA), etoposide (VP-16) cyclophosphamide (CY) with autologous bone marrow rescue (ABMR) in children and young adults with refractory solid or brain tumors. Proc ASCO 1992;11:374.

Namouni F, Doz F, Tanguy MI, et al. High-dose chemotherapy with carboplatin, etoposide and cyclophosphamide followed by a haematopoietic stem cell rescue in patients with high-risk retinoblastoma: a SFOP and SFGM Study. Eur J Cancer 1997;33:2368-75.

Pratt BC, Fontanesi J, Chenaille P, et al. Chemotherapy for extraocular retinoblastoma. Pediatr Hematol Oncol 1994;11:301-9.

Schvarztman E, Chantada G, Fandino A, de Davila MT, Raslawski E, Manzitti J. Results of a stage-based protocol for treatment of retinoblastoma. J Clin Oncol 1996;14:1532-6.

Zelter M, Gonzales G, Schwartz L, et al. Treatment of retinoblastoma: results obtained from a prospective study of 51 patients. Cancer 1988:61:153-60.

Gluckman E, Devergie A, Sohier J, Sauret HJ. Graft-versus-host disease in recipient syngeneic bone marrow transplantation. Lancet 1980;1:253-4.

Morecki S, Margel S, Slavin L. Removal of breast cancer cells by soybean agglutinin in an experimental model for purging human marrow. Cancer Res 1988;48:4573-7.

Hess DA. The immunology of syngeneic/autologous graft-versus-host disease. In: Ferrara LJ, Deeg JH, Burakoff JS eds. Graft-versus-Host Disease. New York: Marcel Dekker 1997:561-86.

Downloads

Published

2018-12-30

Issue

Vol. 11 No. 1: January-March 2001

Section

รายงานผู้ป่วย (Case report)

License

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.